Peroxisome proliferator-activated receptor γ polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Diabetes and Its Complications

• Publication date

  2007-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JDIACOMP.2006.02.006
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Peroxisome proliferator‐activated receptor γ: the more the merrier?

  2005cited by this paper
• Complications of Type 2 Diabetes Among Aboriginal Canadians: prevalence and associated risk factors.

  2005cited by this paper
• Be fit or be sick: peroxisome proliferator-activated receptors are down the road.

  2004cited by this paper
• Genetic Variation in PPARG Encoding Peroxisome Proliferator-Activated Receptor γ Associated With Carotid Atherosclerosis

  2004cited by this paper
• Alanine for Proline Substitution in the Peroxisome Proliferator–Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction

  2003cited by this paper
• Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both?

  2003cited by this paper
• The human peroxisome proliferator-activated receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes.

  2003cited by this paper
• The Peroxisome Proliferator-Activated Receptor-γ2 Pro12Ala Polymorphism

  2002cited by this paper
• Peroxisome proliferator-activated receptor-gamma2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: The Berlin Diabetes Mellitus (BeDiaM) Study.

  2002cited by this paper
• Guilt by association

  2000cited by this paper
• The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes

  2000cited by this paper
• Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress.

  2000cited by this paper
• Peroxisome Proliferator-Activated Receptor-γ2 P12A and Type 2 Diabetes in Canadian Oji-Cree

  2000cited by this paper
• Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis.

  2000cited by this paper
• Validation of a point-of-care assay for the urinary albumin:creatinine ratio.

  1999cited by this paper
• 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association.

  1998cited by this paper
• A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

  1998cited by this paper
• The Prevalence of NIDDM and Associated Risk Factors in Native Canadians

  1997cited by this paper
• The Organization, Promoter Analysis, and Expression of the Human PPARγ Gene*

  1997cited by this paper
• Incidence and prevalence of end-stage renal disease among Ontario's James Bay Cree.

  1992cited by this paper
• Excessive burden of end-state renal disease among Canadian Indians: a national survey.

  1989cited by this paper

• Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy

  2025cites this paper
• The impact of PPARγ and ApoE gene polymorphisms on susceptibility to diabetic kidney disease in type 2 diabetes mellitus: a meta-analysis

  2024cites this paper
• The genetic side of diabetic kidney disease: a review

  2022cites this paper
• PPARG Pro12Ala Polymorphism with CKD in Asians: A Meta-Analysis Combined with a Case-Control Study—A Key for Reaching Null Association

  2020cites this paper
• Peroxisome proliferator activating receptor‐&ggr; and the podocyte

  2016cites this paper
• The PPARγ2 Pro12Ala variant is protective against progression of nephropathy in people with type 2 diabetes

  2015cites this paper
• Association of genetic variants with diabetic nephropathy.

  2014cites this paper
• Peroxisome proliferator‑activated receptor γ polymorphisms as risk factors for dyslipidemia.

  2014cites this paper
• The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis

  2014cites this paper
• Association of peroxisome proliferator-activated receptor γ Pro12Ala gene polymorphism with type 2 diabetic nephropathy risk in Caucasian population

  2014cites this paper
• Role of the ACE ID and PPARG P12A Polymorphisms in Genetic Susceptibility of Diabetic Nephropathy in a South Indian Population

  2013cites this paper
• The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects

  2013cites this paper
• Association Between the PPARG Gene Polymorphism and the Risk of Diabetic Nephropathy: A Meta-Analysis

  2012cites this paper
• PPAR&ggr; as a therapeutic target in diabetic nephropathy and other renal diseases

  2012cites this paper
• Role of PPARs and their isoforms in metabolic disorders related to insulin resistance and diabetes

  2011cites this paper
• PPARγ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies.

  2011cites this paper
• APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians

  2010cites this paper
• Peroxisome Proliferator–Activated Receptor γ Polymorphism Pro12Ala Is Associated With Nephropathy in Type 2 Diabetes

  2010cites this paper
• Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.

  2009cites this paper
• PPARγ2Pro12Ala Polymorphism and Human Health

  2009cites this paper
• [Role of dietary lipids in diabetic nephropathy].

  2009cites this paper
• Pro12Ala Polymorphism in the PPARG Gene Contributes to the Development of Diabetic Nephropathy in Chinese Type 2 Diabetic Patients

  2009cites this paper
• Retinoid X receptor heterodimer variants and cardiovascular risk factors.

  2009cites this paper
• Peroxisome Proliferator-Activated Receptor Gamma Agonists in Kidney Disease – Future Promise, Present Fears

  2009cites this paper
• Papel dos lipídeos da dieta na nefropatia diabética Role of dietary lipids in diabetic nephropathy

  2009cites this paper
• PPARγ in Kidney Physiology and Pathophysiology

  2009cites this paper
• Association Study of the Peroxisome Proliferators-Activated Receptor γ2 Pro12Ala Polymorphism with Diabetic Nephropathy

  2008cites this paper
• ReviewArticle PPARγ in Kidney Physiology and Pathophysiology

  2008cites this paper
• Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease.

  2008cites this paper
• Gene and protein markers of diabetic nephropathy.

  2007cites this paper